- Home
- ELPC vs RYTM Comparison
ELPC vs RYTM Comparison
Compare ELPC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELPC
- RYTM
- Stock Information
- Founded
- ELPC 1954
- RYTM 2008
- Country
- ELPC Brazil
- RYTM United States
- Employees
- ELPC N/A
- RYTM N/A
- Industry
- ELPC Electric Utilities: Central
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- ELPC Utilities
- RYTM Health Care
- Exchange
- ELPC Nasdaq
- RYTM Nasdaq
- Market Cap
- ELPC 6.1B
- RYTM 6.4B
- IPO Year
- ELPC N/A
- RYTM 2017
- Fundamental
- Price
- ELPC $9.37
- RYTM $108.50
- Analyst Decision
- ELPC
- RYTM Strong Buy
- Analyst Count
- ELPC 0
- RYTM 13
- Target Price
- ELPC N/A
- RYTM $110.38
- AVG Volume (30 Days)
- ELPC 1.6K
- RYTM 544.4K
- Earning Date
- ELPC 01-01-0001
- RYTM 11-04-2025
- Dividend Yield
- ELPC 4.34%
- RYTM N/A
- EPS Growth
- ELPC 30.24
- RYTM N/A
- EPS
- ELPC 0.19
- RYTM N/A
- Revenue
- ELPC $4,381,150,343.00
- RYTM $156,287,000.00
- Revenue This Year
- ELPC N/A
- RYTM $46.14
- Revenue Next Year
- ELPC $6.95
- RYTM $63.37
- P/E Ratio
- ELPC $12.79
- RYTM N/A
- Revenue Growth
- ELPC 8.47
- RYTM 53.55
- 52 Week Low
- ELPC $5.04
- RYTM $45.91
- 52 Week High
- ELPC $9.42
- RYTM $113.91
- Technical
- Relative Strength Index (RSI)
- ELPC 65.69
- RYTM 60.77
- Support Level
- ELPC $8.35
- RYTM $105.40
- Resistance Level
- ELPC $8.58
- RYTM $113.56
- Average True Range (ATR)
- ELPC 0.16
- RYTM 4.37
- MACD
- ELPC 0.05
- RYTM 0.78
- Stochastic Oscillator
- ELPC 95.75
- RYTM 69.28
About ELPC Companhia Paranaense de Energia (COPEL) (each representing four (4))
Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Services, and Holding. The majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.